Market Overview

UPDATE: Benchmark Initiates BioCLinica with Buy, $8 PT as Possible M&A Target


Benchmark initiates its coverage on BioClinica (NASDAQ: BIOC) with a Buy rating and a price target of $8.

Benchmark says, "Last week we spent a day in Philadelphia at the Drug Information Association tradeshow, which was held June 24-28. This event highlights services to the pharmaceutical industry including eClinical software vendors and CROs. Conference attendance and the corporate events appeared notably lighter than in years past but we were pleasantly surprised that generally, firms are growing, profitable and carry an optimistic outlook. In addition to healthy sector business dynamics, we sense that further M&A activity could support sector valuation. We feel BioClinica is an excellent buy now at 12.1x our forecast current year $0.40 nonGAAP EPS, or 10.1x, excluding $0.77 per share in cash."

BIOC closed at $4.80 a share on Monday.

Latest Ratings for BIOC

Mar 2019Maxim GroupInitiates Coverage OnBuy
Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings


Related Articles (BIOC)

View Comments and Join the Discussion!

Posted-In: BenchmarkAnalyst Color Price Target Initiation Intraday Update Analyst Ratings

Latest Ratings

MOHB of A SecuritiesUpgrades
SAGECanaccord GenuityMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at